Rifaximin

Generic Name
Rifaximin
Brand Names
Xifaxan, Zaxine
Drug Type
Small Molecule
Chemical Formula
C43H51N3O11
CAS Number
80621-81-4
Unique Ingredient Identifier
L36O5T016N
Background

Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of overt hepatic encephalop...

Indication

Rifaximin has multiple indications by the FDA: for the treatment of patients (≥12 years of age) with traveller's diarrhea caused by noninvasive strains of Escherichia coli; for the reduction of overt hepatic encephalopathy recurrence in patients ≥18 years of age; and in May 2015 it was approved for irritable bowel syndrome with diarrhea (IBS-D) treatment in ...

Associated Conditions
Bacterial Infections, Clostridium difficile infection recurrence, Hepatic Encephalopathy (HE), Irritable Bowel Syndrome (IBS), Traveler's Diarrhea
Associated Therapies
-
Clinical Trials
Related News

Effects of Rifaximin in Patients With Acute Alcoholic Hepatitis

First Posted Date
2014-04-17
Last Posted Date
2016-11-04
Lead Sponsor
Hospital Universitari Vall d'Hebron Research Institute
Target Recruit Count
29
Registration Number
NCT02116556
Locations
🇪🇸

Hospital del Mar, Barcelona, Spain

🇪🇸

Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

🇪🇸

Vall d'Hebron Hospital, Barcelona, Spain

and more 1 locations

A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure

Phase 3
Withdrawn
Conditions
Hepatic Encephalopathy
Interventions
Drug: Rifaximin
Drug: Lactulose
First Posted Date
2014-03-13
Last Posted Date
2016-03-02
Lead Sponsor
NYU Langone Health
Registration Number
NCT02086825
Locations
🇺🇸

New York University Langone Medical Center, New York, New York, United States

Rifaximin Predicts the Complications of Decompensated Cirrhosis

Phase 4
Conditions
Cirrhosis
Interventions
Drug: rifaximin
First Posted Date
2014-02-28
Last Posted Date
2014-02-28
Lead Sponsor
Shanghai Changzheng Hospital
Target Recruit Count
250
Registration Number
NCT02074280
Locations
🇨🇳

Shanghai changzheng Hospital, Shanghai, Shanghai, China

Immunohistology in USDD and Correlation Between Bacterial Flora and Phlogosis

Phase 4
Completed
Conditions
Diverticular Disease
Interventions
Drug: Rifaximin
First Posted Date
2014-02-21
Last Posted Date
2014-02-21
Lead Sponsor
Catholic University of the Sacred Heart
Target Recruit Count
61
Registration Number
NCT02068482
Locations
🇮🇹

Cattholic University of the Sacre Heart, Rome, Italy

Rifaximin vs Placebo for the Prevention of Encephalopathy in Patients Treated by TIPS

Phase 3
Completed
Conditions
Cirrhosis
Interventions
Drug: placebo
Drug: Rifaximin
First Posted Date
2013-12-19
Last Posted Date
2020-04-24
Lead Sponsor
University Hospital, Toulouse
Target Recruit Count
211
Registration Number
NCT02016196
Locations
🇫🇷

CHU Bordeaux, Bordeaux, France

🇫🇷

CHRU Lille, Lille, France

🇫🇷

CHU Marseille, Marseille, France

and more 10 locations

Rifaximin for the Secondary Prevention of Spontaneous Bacterial Peritonitis Recurrence in Cirrhotic Patients

First Posted Date
2013-12-13
Last Posted Date
2017-04-25
Lead Sponsor
Seoul National University Hospital
Registration Number
NCT02011841
Locations
🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

The Effects of Rifaximin Therapy in Irritable Bowel Syndrome

Not Applicable
Completed
Conditions
IBS
Interventions
Drug: placebo
Drug: Rifaximin
First Posted Date
2013-12-12
Last Posted Date
2013-12-12
Lead Sponsor
Bezmialem Vakif University
Target Recruit Count
500
Registration Number
NCT02009618
Locations
🇹🇷

Bezmialem Vakıf University, Gastroenterology Clinic, Istanbul, Turkey

Efficacy of Rifaximin on Hepatosteatosis and Steatohepatitis Patients

Not Applicable
Completed
Conditions
Fatty Liver
Steatohepatitis
Interventions
Drug: Rifaximin
First Posted Date
2013-12-12
Last Posted Date
2014-05-16
Lead Sponsor
Bezmialem Vakif University
Target Recruit Count
42
Registration Number
NCT02009592
Locations
🇹🇷

Bezmialem Vakif University, Istanbul, Turkey

Pilot Study Of The Effect Of Rifaximin On B-Cell Dysregulation In Cirrhosis

Not Applicable
Terminated
Conditions
Liver Cirrhosis
Chronic Hepatitis C
Interventions
Drug: Rifaximin
Drug: Placebo
First Posted Date
2013-09-26
Last Posted Date
2021-03-11
Lead Sponsor
David E. Kaplan, MD MSc
Target Recruit Count
13
Registration Number
NCT01951209
Locations
🇺🇸

Philadelphia VA Medical Center, Philadelphia, Pennsylvania, United States

The Rifaximin Study in CVID

Phase 4
Completed
Conditions
Common Variable Immunodeficiency (CVID)
Interventions
Drug: Rifaximin
First Posted Date
2013-09-20
Last Posted Date
2015-04-24
Lead Sponsor
Oslo University Hospital
Target Recruit Count
40
Registration Number
NCT01946906
Locations
🇳🇴

Oslo University Hospital, Oslo, Norway

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy